1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme - Pipeline Review, H1 2020, provides an overview of the Glioblastoma Multiforme (Oncology) pipeline landscape.
Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glioblastoma Multiforme (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 130, 94, 2, 13, 198, 43 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 14, 14, 3, 53 and 9 molecules, respectively.
Glioblastoma Multiforme (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (Oncology).
- The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glioblastoma Multiforme (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glioblastoma Multiforme (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Glioblastoma Multiforme (GBM) - Overview
- Glioblastoma Multiforme (GBM) - Therapeutics Development
- Glioblastoma Multiforme (GBM) - Therapeutics Assessment
- Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
- Glioblastoma Multiforme (GBM) - Drug Profiles
- Glioblastoma Multiforme (GBM) - Dormant Projects
- Glioblastoma Multiforme (GBM) - Discontinued Products
- Glioblastoma Multiforme (GBM) - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by 1st Bio Therapeutics Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by 1ST Biotherapeutics Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by 4D Pharma Plc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Aadi Bioscience Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by ABM Therapeutics Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Accendatech Au Pty Ltd, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Adastra Pharmaceuticals Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Aettis Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by AiVita Biomedical Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Allianz Pharmascience Ltd, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Alterity Therapeutics Ltd, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by MiReven Pty Ltd, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Molecular Targeting Technologies Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Molecular Templates Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech LLC, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Multimmune GmbH, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Mustang Bio Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Nanjing Bioheng Biotech Co Ltd, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Nanjing KAEDI Biotech Inc, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Nanjing Legend Biotech Co Ltd, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H1 2020
- Glioblastoma Multiforme (GBM) - Pipeline by NanoPharmaceuticals LLC, H1 2020
List of Figures
- Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1st Bio Therapeutics Inc
- 1ST Biotherapeutics Inc
- 4D Pharma Plc
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Aadi Bioscience Inc
- AbbVie Inc
- ABM Therapeutics Inc
- Accendatech Au Pty Ltd
- Actuate Therapeutics Inc
- Adastra Pharmaceuticals Inc
- Adlai Nortye Biopharma Co Ltd
- Aduro BioTech Inc
- Advanced Accelerator Applications SA
- Advenchen Laboratories LLC
- Aettis Inc
- Affimed GmbH
- Agenus Inc
- AiVita Biomedical Inc
- Allianz Pharmascience Ltd
- Alterity Therapeutics Ltd
- Amal Therapeutics SA
- Amasa Technologies Inc
- Ambrx Inc
- Amgen Inc
- Anew Oncology Inc
- AngioChem Inc
- apceth Biopharma GmbH
- Apexigen Inc
- APIM Therapeutics AS
- Apogenix AG
- Apollomics Inc
- Apotex Inc
- Aptamer Sciences Inc
- Argonaut Therapeutics Ltd
- Arog Pharmaceuticals Inc
- Arrien Pharmaceuticals LLC
- Arrogene Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Athenex Inc
- Aurora BioPharma Inc
- Avalia Immunotherapies Ltd
- Aveta Biomics Inc
- Avid Chemotherapeutics LLC
- Avidin Ltd
- Basilea Pharmaceutica Ltd
- Batu Biologics Inc
- Bayer AG
- BeiGene Ltd
- Beijing Eastern Biotech Co Ltd
- Berg LLC
- BerGenBio ASA
- Beta Pharma Inc
- Bexion Pharmaceuticals LLC
- BeyondBio Inc
- BeyondSpring Inc
- Bio-Path Holdings Inc
- Bio-Thera Solutions Ltd
- Bioasis Technologies Inc
- Biocon Ltd
- BioEclipse Therapeutics Inc
- BioIntegrator Ltd
- BioNTech SE
- Biosion Inc
- Biovista Inc
- BioXpress Therapeutics SA
- Black Diamond Therapeutics Inc
- Boehringer Ingelheim International GmbH
- Boryung ViGenCell Inc
- Boston Biomedical Inc
- BoYuan RunSheng Pharma Hangzhou Co Ltd
- Breakpoint Therapeutics GmbH
- Bristol-Myers Squibb Co
- Candel Therapeutics
- Cantex Pharmaceuticals Inc
- CARsgen Therapeutics Ltd
- CDG Therapeutics Inc
- Cell Medicine Cooperation
- CellCure
- Celldex Therapeutics Inc
- Cellestia Biotech AG
- Cellivery Therapeutics Inc
- Cellmid Ltd
- Cellworks Group Inc
- Celsion Corp
- Celularity Inc
- CHA Biotech Co Ltd
- Cloaked Therapeutics LLC
- CNS Pharmaceuticals Inc
- Cotinga Pharmaceuticals Inc
- Curtana Pharmaceuticals Inc
- Cynata Therapeutics Ltd
- Cytodyn Inc
- CytoVac AS
- Daiichi Sankyo Co Ltd
- Dalriada Therapeutics Inc
- Deciphera Pharmaceuticals Inc
- DEKK-TEC Inc
- DelMar Pharmaceuticals Inc
- Denovo Biopharma LLC
- DevaCell Inc
- Diakonos Research Ltd
- Diffusion Pharmaceuticals Inc
- Diverse Biotech Inc
- Divide and Conquer Ltd
- DNAtrix Inc
- Dong-A ST Co Ltd
- Dr. Reddy's Laboratories Ltd
- DualTpharma BV
- Ecrins Therapeutics SAS
- EirGenix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Empirica Therapeutics Inc
- ENB Therapeutics LLC
- EnduRx Pharmaceuticals Inc
- EnGeneIC Ltd
- Enochian Biosciences Inc
- Enterome Bioscience SA
- EntreChem SL
- EpicentRx Inc
- EpiDrugs Discovery
- Epigene Therapeutics Inc
- Epygen Biotech Pvt Ltd
- ERC Belgium SA
- ERYTECH Pharma SA
- Eutilex Co Ltd
- Ever Supreme Bio Technology Co Ltd
- Everfront Biotech Inc
- Evgen Pharma Plc
- F. Hoffmann-La Roche Ltd
- Falcon Therapeutics Inc
- Faron Pharmaceuticals Oy
- Felicitex Therapeutics Inc
- FirstString Research Inc
- Flag Therapeutics Inc
- Flavocure Biotech LLC
- Fujifilm Holdings Corp
- Fusion Antibodies Plc
- Galapagos NV
- GC Pharma
- Gene Techno Science Co Ltd
- Geneius Biotechnology Inc
- Genenta Science srl
- Genentech Inc
- Geneos Therapeutics Inc
- Genexine Inc
- Genisphere LLC
- Genomefrontier Therapeutics Inc
- Genoscience Pharma
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- GlioCure SAS
- GlioPharma ApS
- GO Therapeutics Inc
- GtreeBNT Co Ltd
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Hamlet Pharma AB
- Hanmi Pharmaceuticals Co Ltd
- Hebei Senlang Biotechnology Inc Ltd
- Hemispherian AS
- Hope Biosciences LLC
- HOX Therapeutics Ltd
- Humanigen Inc
- Hunan Siweikang Therapeutics Ltd
- Hutchison MediPharma Ltd
- Hyperstem Therapeutics Inc
- i2 Pharmaceuticals Inc
- Ibex Biosciences LLC
- Immatics Biotechnologies GmbH
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- Immunitor Inc
- ImmunityBio Inc
- ImmunoCellular Therapeutics Ltd
- Immunomedics Inc
- Immunomet Therapeutics Inc
- Immunomic Therapeutics Inc
- ImmunoRestoration LLC
- IMV Inc
- Imvax Inc
- Incysus Therapeutics Inc
- Incyte Corp
- Infinity Pharmaceuticals Inc
- Innovation Pharmaceuticals Inc
- Inovio Pharmaceuticals Inc
- InSight Biopharmaceuticals Ltd
- Instituto Biomar SA
- IntelliStem Technologies Inc
- Intensity Therapeutics Inc
- InterLeukin Combinatorial Therapies Inc
- Invectys SA
- Ipsen SA
- ISA Pharmaceuticals BV
- Istari Oncology Inc
- ITM Isotopen Technologien Munchen AG
- Janpix Inc
- Jay Pharma Inc
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Johnson & Johnson
- Joseah Biopharma Co Ltd
- Jubilant Therapeutics Inc
- Juno Therapeutics Inc
- JW CreaGene Co Ltd
- Kadmon Corp LLC
- Kalgene Pharmaceuticals Inc
- Kancera AB
- Karus Therapeutics Ltd
- Karyopharm Therapeutics Inc
- Kazia Therapeutics Ltd
- Komipharm International Co Ltd
- Kringle Pharma Inc
- Kyorin Pharmaceutical Co Ltd
- Lacerta Therapeutics Inc
- Lantern Pharma Inc
- Lauren Sciences LLC
- LeadInvent Pharma Inc
- Lin Bioscience Inc
- Lipopharma Therapeutics SL
- Lixte Biotechnology Holdings Inc
- Lumos Pharma Inc
- Luye Pharma Group Ltd
- LynkCell Inc
- MacroGenics Inc
- Marino Biotechnology Co Ltd
- Medesis Pharma SA
- Medical Guidance Systems LLC
- Medicenna Therapeutics Corp
- Medicon Pharmaceuticals Inc
- Medisun Precision Medicine Ltd
- MedPacto Inc
- MELEMA Pharma GmbH
- Merck & Co Inc
- Merck KGaA
- Meryx Inc
- Metis Precision Medicine
- MetVital Inc
- MGC Pharmaceuticals Ltd
- Midatech Pharma Plc
- Millennium Pharmaceuticals Inc
- MimiVax LLC
- MiReven Pty Ltd
- Molecular Targeting Technologies Inc
- Molecular Templates Inc
- Moleculin Biotech LLC
- Multimmune GmbH
- Mustang Bio Inc
- Mycenax Biotech Inc
- Nanjing Bioheng Biotech Co Ltd
- Nanjing KAEDI Biotech Inc
- Nanjing Legend Biotech Co Ltd
- Nanomerics Ltd
- NanoPharmaceuticals LLC
- NantKwest Inc
- Nascent Biotech Inc
- NatureWise Biotech & Medicals Corp
- Nektar Therapeutics
- Neonc Technologies Inc
- NMS Group SpA
- Northlake International LLC
- Northwest Biotherapeutics Inc
- Novartis AG
- Novellus Inc
- Noxopharm Ltd
- Noxxon Pharma AG
- NuvOx Pharma LLC
- OGD2 Pharma SAS
- Omniox Inc
- OncoArendi Therapeutics SA
- Oncoceutics Inc
- Oncodesign SA
- Oncologie Inc
- Oncology Venture U.S. Inc
- Oncolytics Biotech Inc
- Onconova Therapeutics Inc
- OncoResponse Inc
- Oncorus Inc
- OncoRx Pharmaceuticals Inc
- OncoSynergy Inc
- Oncotelic Inc
- Oncternal Therapeutics
- Ono Pharmaceutical Co Ltd
- Origenis GmbH
- Oryx GmbH & Co KG
- Ossianix Inc
- Ovensa Inc
- Parabon NanoLabs
- Pascal Biosciences Inc
- Patrys Ltd
- PENAO Pty Ltd
- Peptomyc SL
- Pfizer Inc
- Phanes Therapeutics Inc
- Pharma Mar SA
- PharmAbcine Inc
- Pharmicell Co Ltd
- Phoenix Biotechnology Inc
- Phost'IN SAS
- Photonamic GmbH & Co KG
- Plex Pharmaceuticals Inc
- Plus Therapeutics Inc
- Prelude Therapeutics Inc
- Prestige BioPharma Pte Ltd
- Preveceutical Medical Inc
- Primevax Immuno Oncology Inc
- PTC Therapeutics Inc
- Puma Biotechnology Inc
- QED Therapeutics Inc
- Quadriga BioSciences Inc
- Refuge Biotechnologies Inc
- Regeneron Pharmaceuticals Inc
- Reglagene LLC
- Regulus Therapeutics Inc
- ReNeuron Group Plc
- Revolution Medicines Inc
- Rgenix Inc
- Richter Gedeon Nyrt
- Ridgeline Therapeutics LLC
- Rottapharm Biotech Srl
- Rznomics Inc
- Safe Save Medical Cell Sciences & Technology Co Ltd
- Salarius Pharmaceuticals Inc
- Sanofi
- Sapience Therapeutics Inc
- Scancell Holdings Plc
- Seagull Labs (I) Pvt Ltd
- Seneca Therapeutics Inc
- Sentinel Oncology Ltd
- Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- Shenzhen BinDeBio Ltd
- Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
- SignalChem Lifesciences Corp
- SignPath Pharma Inc
- Silenseed Ltd
- Singh Biotechnology LLC
- SixFold Bioscience Ltd
- SL Bigen Inc
- SL VaxiGen Inc
- SOM Biotech SL
- Speer Medical Technologies LLC
- STAT3 Therapeutics Inc
- Stcube Inc
- Stella Therapeutics Inc
- StemGen SpA
- Sumitomo Dainippon Pharma Co Ltd
- Suntec Medical (Taiwan) Inc
- Susavion Biosciences Inc
- Suzhou JiSheng Pharmaceutical Co Ltd
- Suzhou Neupharma Co Ltd
- Suzhou Stainwei Biotech Inc
- Synactix Pharmaceuticals Inc
- Synchronicity Pharma Inc
- Synermore Biologics Co Ltd
- SyntheX Inc
- Tactical Therapeutics Inc
- Taiho Oncology Inc
- Targinta AB
- Telo Therapeutics Inc
- Telomium SAS
- The Palo Alto Research Center
- TheraBiologics Inc
- Theralase Technologies Inc
- Therapeia GmbH & Co KG
- TheraPten Biosciences Inc
- Titan Pharmaceuticals Inc
- Tmunity Therapeutics Inc
- TRACON Pharmaceuticals Inc
- Transcode Therapeutics Inc
- Transgene SA
- Transtarget Inc
- Turning Point Therapeutics Inc
- TVAX Biomedical Inc
- Tyme Technologies Inc
- Upsher-Smith Laboratories Inc
- Vanquish Oncology Inc
- Vascular Biogenics Ltd
- Vault Pharma Inc
- Vaximm AG
- VBI Vaccines Inc
- Vigeo Therapeutics Inc
- ViruCure Therapeutics Ltd
- Vivacitas Oncology Inc
- Wayshine Biopharma Inc
- WindMIL Therapeutics Inc
- WPD Pharmaceuticals Inc
- X4 Pharmaceuticals Inc
- Xonovo Inc
- Yooyoung Pharm Co Ltd
- Zata Pharmaceuticals Inc
- Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
- ZIOPHARM Oncology Inc
